Please assess the completion status of the following clinical trial:

Trial Title: Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has platinum-sensitive, recurrent ovarian, fallopian-tube or peritoneal cancer. Platinum sensitivity is defined as complete clinical remission after frontline chemotherapy lasting greater than 6 months~* Patient has completed at least 2 courses of platinum-based chemotherapy with a PR or CR as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.139 or a CA-125 response, according to Gynecological Cancer InterGroup (GCIG) criteria40~* BRCA testing required (results not needed for registration)~* ECOG performance status score of 0, 1, or 2 (See Appendix A)~* Life expectancy greater than 6 months~* Normal organ and marrow function as defined: Absolute neutrophil count (ANC) ≥ 1.5 x 109/L; Platelets ≥ 100 x 109/L; Hemoglobin (Hgb) ≥ 8 g/dL (blood transfusions to reach this amount are allowed); Serum creatinine ≤ 1.5 mg/dL; Total serum bilirubin ≤ 1.5 x ULN; AST and ALT ≤ 2.5 x ULN~* Able to take oral medication~* Not pregnant and not breastfeeding~* Able to understand and willingness to sign a written informed consent document~* Patients must be enrolled within 8 weeks of completing last cycle of chemotherapy~Exclusion Criteria:~* Patient has had a prior invasive malignancy diagnosed within the last five years (except \[1\] non-melanoma skin cancer or \[2\] prior in situ carcinoma of the cervix or breast \[3\] has been without evidence of invasive disease for greater than 3 years)~* Patients receiving any other investigational agents~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib~* Uncontrolled intercurrent illness that could affect their participation in the study including, but not limited to, ongoing or active infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; known inadequately controlled hypertension; significant pulmonary disease including dyspnea at rest, patients requiring supplemental oxygen, or poor pulmonary reserve; or psychiatric illness/social situations that would limit compliance with study requirements~* Impairment of gastrointestinal function or disease that may significantly alter the absorption of olaparib~* Patients who have received prior treatment with a PARP inhibitor~* History of noncompliance to medical regimens

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Olaparib (Type: EXPERIMENTAL): Olaparib dosed at 300mg orally twice daily, started when CA125 rises by two-fold of nadir value.

Based on this trial design, predict the completion outcome and termination type (if applicable).